Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer
{{output}}
There is a growing body of evidence that the optimal adjuvant endocrine therapy for hormone-sensitive breast cancer in postmenopausal women should include an aromatase inhibitor. However, further research is required to establish the optimal aromatase inhibito... ...
